Scholtz & Company’s Teladoc Health TDOC Stock Holding History

Scholtz & Company’s Portfolio TDOC Stock Details TDOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-40,105	Closed	-$7.29M	–	77
2021 Q1	$7.29M	Buy	40,105 +760	+2%	+$176K	2.77%	8
2020 Q4	$7.87M	Buy	39,345 +2,866	+8%	+$583K	3.07%	9
2020 Q3	$8M	Buy	36,479 +159	+0.4%	+$33.7K	3.49%	8
2020 Q2	$6.93M	Sell	36,320 -5,705	-14%	-$1,000K	3.46%	8
2020 Q1	$6.51M	Sell	42,025 -552	-1%	-$64.2K	4.99%	6
2019 Q4	$3.56M	Buy	42,577 +325	+0.8%	+$24.7K	2.07%	20
2019 Q3	$2.86M	Buy	42,252 +5,820	+16%	+$383K	1.91%	17
2019 Q2	$2.42M	Buy	36,432 +4,717	+15%	+$275K	1.57%	28
2019 Q1	$1.76M	Buy	+31,715	New	+$1.94M	1.18%	30
2018 Q4	–	Sell	-35,735	Closed	-$3.09M	–	60
2018 Q3	$3.09M	Buy	35,735 +17,934	+101%	+$1.28M	1.95%	21
2018 Q2	$1.03M	Buy	+17,801	New	+$869K	0.72%	32

Other funds holding TDOC

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

GCGM

General Catalyst Group Management Cambridge, Massachusetts $189M AUM 10.96% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Scholtz & Company's TDOC Position: Q2 2021 in Review

Scholtz & Company sold out of Teladoc Health (TDOC) in Q2 2021, closing a stake of 40,105 shares — an estimated $7.29M sold.

Scholtz & Company first reported a position in TDOC in Q2 2018 and held it in 11 quarters. The position peaked at $8M in Q3 2020. 829 funds tracked by Wall St. Rank hold TDOC as of Q2 2021.

Scholtz & Company reported no remaining Teladoc Health position as of Q2 2021 after selling out during the quarter.
Scholtz & Company sold 40,105 Teladoc Health shares in Q2 2021, an estimated $7.29M.
Scholtz & Company first reported a position in Teladoc Health in Q2 2018 and held it in 11 quarters.
Scholtz & Company's Teladoc Health position peaked at $8M in Q3 2020.
829 funds tracked by Wall St. Rank held Teladoc Health as of Q2 2021.

Based on Scholtz & Company's 13F filing for Q2 2021, filed 9 Aug 2021.